Results 121 to 130 of about 87,604,756 (316)

Towards the One Exposome: harnessing artificial intelligence and digital health technologies across One Health toxicology, new approach methodologies, and environmental public health

Frontiers in Public Health
The One Exposome framework integrates exposomics, One Health toxicology, New Approach Methodologies (NAMs) and artificial intelligence to advance environmental health from reactive risk assessment towards predictive, preventive, and participatory science.
Sandra Coecke, Thomas Hartung, Thomas Hartung   +2 more
doaj   +1 more source

Metastatic niche shaped by host factors influences disseminated cancer cell fate

FEBS Letters, EarlyView.
Metastasis is shaped not only by cancer cells but also by the environments they encounter. This review explores how factors such as aging, diet, the microbiome, lifestyle, and environmental exposures remodel organ‐specific niches in the lung, liver, bone, and brain, influencing where metastatic cells survive, remain dormant, or grow, and ultimately ...
Gwennan Delyth Ward, Álvaro Ruiz‐Tabas, Patricia Altea‐Manzano   +2 more
wiley   +1 more source

Membrane composition and thermodynamic identity as boundaries of life for synthetic cell research

FEBS Letters, EarlyView.
What makes a cell a cell? The boundary of a living cell is not just a wall. Read as a Markov blanket, the membrane separates internal from external states, generating identity and non‐equilibrium order. Can this identity be rebuilt from scratch in a synthetic cell?
Caterina Presutti, Bert Poolman
wiley   +1 more source

AI: the Apollo guidance computer of the Exposome moonshot

Frontiers in Artificial Intelligence
The Exposome—the totality of environmental exposures across a lifetime—remains one of the most significant challenges in understanding and preventing human disease.
Fenna C. M. Sillé, Thomas Hartung, Thomas Hartung, Thomas Hartung   +3 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Alternatives in animal testing. [PDF]

Environmental Health Perspectives, 1996
openaire   +2 more sources

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Navigating the unseen peril: safeguarding medical imaging in the age of AI

Frontiers in Artificial Intelligence
In response to the increasing significance of artificial intelligence (AI) in healthcare, there has been increased attention – including a Presidential executive order to create an AI Safety Institute – to the potential threats posed by AI.
Alexandra Maertens, Steve Brykman, Thomas Hartung, Thomas Hartung, Andrei Gafita, Harrison Bai, David Hoelzer, Ed Skoudis, Channing Judith Paller   +8 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Induced cytotoxicity revealed species diversity of rat and human lung tissue by repeated chemical exposure

, 2022
S.53The use of high animal numbers and the suffering of animals in experiments such as repeated dose toxicity studies (RDT) demand for alternative test approaches. This can be done by grouping of chemicals to reduce in vivo studies.
Braubach, Peter, Sewald, Katherina, Escher, Sylvia E., Braun, Armin, Danov, Olga, Vorgrimmler, David, Warnecke, Gregor, Schröder, Katrin, Jonigk, Danny   +8 more
core   +1 more source